Treatment of atypical hemolytic uremic syndrome and thrombotic microangiopathies: A focus on eculizumab

American Journal of Kidney Diseases

Volumn 61, Issue 2, 2013, Pages 289-299

  Schmidtko, Jan ^a,b   Peine, Sven ^c   El Housseini, Youssef ^a   Pascual, Manuel ^b   Meier, Pascal ^a,b  

^a Laboratoire Cantonal   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

atypical hemolytic uremic syndrome; complement; eculizumab; Thrombotic microangiopathy

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4 BINDING PROTEIN; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; CREATININE; ECULIZUMAB; LACTATE DEHYDROGENASE; MEMBRANE COFACTOR PROTEIN; NEUTRALIZING ANTIBODY; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL (TOPIC); CREATININE BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; GENE MUTATION; HEMOLYSIS; HEMOLYTIC UREMIC SYNDROME; HUMAN; KIDNEY FAILURE; MENINGOCOCCOSIS; QUALITY OF LIFE; SINGLE DRUG DOSE; THROMBOTIC THROMBOCYTOPENIC PURPURA; TREATMENT RESPONSE;

EID: 84872336333     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.07.028     Document Type: Review

References (83)

1. P. Hillmen, C. Hall, J.C. Marsh Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria N Engl J Med 350 6 2004 552 559
2. A. Hill, P. Hillmen, S.J. Richards Sustained response and long-term safety of eculizumab in paroxysmal nocturnal hemoglobinuria Blood 106 7 2005 2559 2565
3. R.A. Brodsky, N.S. Young, E. Antonioli Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria Blood 111 4 2008 1840 1847
4. P. Hillmen, N.S. Young, J. Schubert The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria N Engl J Med 355 12 2006 1233 1243
5. J. Nürnberger, T. Philipp, O. Witzke Eculizumab for atypical hemolytic-uremic syndrome N Engl J Med 360 5 2009 542 544
6. R.A. Gruppo, R.P. Rother Eculizumab for congenital atypical hemolytic-uremic syndrome N Engl J Med 360 5 2009 544 546
7. C. Frank, D. Werber, J. Cramer Epidemic profile of Shiga-toxin-producing Escherichia coli O104:H4 outbreak in Germany N Engl J Med 365 19 2011 1771 1780
8. A.L. Sellier-Leclerc, V. Frémeaux-Bacchi, M.A. Dragon-Durey Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome J Am Soc Nephrol 18 8 2007 2392 2400
9. B.J. Ballermann Endothelial cell activation Kidney Int 53 6 1998 1810 1826
10. P. Ruggenenti, P. Cravedi, G. Remuzzi Thrombotic microangiopathies, including hemolytic uremic syndrome J. Floege, R. Johnson, J. Feehally, Comprehensive Clinical Nephrology Vol 1 2010 Elsevier Saunders St Louis, MO 344 355
11. E. Moschcowitz An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries; an undescribed disease Am J Med 13 5 1952 567 569
12. M. Furlan, R. Robles, M. Galbusera von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome N Engl J Med 339 22 1998 1578 1584
13. J.L. Moake Moschcowitz, multimers, and metalloprotease N Engl J Med 339 22 1998 1629 1631
14. H.M. Tsai, E.C. Lian Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura N Engl J Med 339 22 1998 1585 1594
15. D. Orth, A.B. Khan, A. Naim Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome J Immunol 182 10 2009 6394 6400
16. M. Morigi, M. Galbusera, S. Gastoldi Alternative pathway activation of complement by Shiga toxin promotes exuberant C3a formation that triggers microvascular thrombosis J Immunol 187 1 2011 172 180
17. A.L. Ståhl, L. Sartz, D. Karpman Complement activation on platelet-leukocyte complexes and microparticles in enterohemorrhagic Escherichia coli-induced hemolytic uremic syndrome Blood 117 20 2011 5503 5513
18. A.L. Ståhl, F. Vaziri-Sani, S. Heinen Factor H dysfunction in patients with atypical hemolytic uremic syndrome contributes to complement deposition on platelets and their activation Blood 111 11 2008 5307 5315
19. J.M. Thurman, R. Marians, W. Emlen Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome Clin J Am Soc Nephrol 4 12 2009 1920 1924
20. J.P. Atkinson, M.K. Liszewski, A. Richards, D. Kavanagh, E.A. Moulton Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue Ann N Y Acad Sci 1056 2005 144 152
21. L.B. Zimmerhackl, N. Besbas, T. Jungraithmayr Epidemiology, clinical presentation, and pathophysiology of atypical and recurrent hemolytic uremic syndrome Semin Thromb Hemost 32 2 2006 113 120
22. T.S. Jokiranta, P.F. Zipfel, V. Frémeaux-Bacchi, C.M. Taylor, T.J. Goodship, M. Noris Where next with atypical hemolytic uremic syndrome? Mol Immunol 44 16 2007 3889 3900
23. A.M. Blom, F. Bergström, M. Edey A novel non-synonymous polymorphism (p.Arg240His) in C4b-binding protein is associated with atypical hemolytic uremic syndrome and leads to impaired alternative pathway cofactor activity J Immunol 180 9 2008 6385 6391
24. C. Loirat, M. Noris, V. Fremeaux-Bacchi Complement and the atypical hemolytic uremic syndrome in children Pediatr Nephrol 23 11 2008 1957 1972
25. D. Ricklin, J.D. Lambris Complement-targeted therapeutics Nat Biotechnol 25 11 2007 1265 1275
26. L.A. Matis, S.A. Rollins Complement-specific antibodies: designing novel anti-inflammatories Nat Med 1 8 1995 839 842
27. D. Karpman, M. Manea, F. Vaziri-Sani, A.L. Stahl, A.C. Kristoffersson Platelet activation in hemolytic uremic syndrome Semin Thromb Hemost 32 2 2006 128 145
28. T. Manuelian, J. Hellwage, S. Meri Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome J Clin Invest 111 8 2003 1181 1190
29. S. Heinen, M. Józsi, A. Hartmann Hemolytic uremic syndrome: a factor H mutation (E1172Stop) causes defective complement control at the surface of endothelial cells J Am Soc Nephrol 18 2 2007 506 514
30. P.F. Zipfel, C. Skerka Complement regulators and inhibitory proteins Nat Rev Immunol 9 10 2009 729 740
31. P.F. Zipfel, S. Heinen, C. Skerka Thrombotic microangiopathies: new insights and new challenges Curr Opin Nephrol Hypertens 19 4 2010 372 378
32. A.X. Garg, R.S. Suri, N. Barrowman Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression JAMA 290 10 2003 1360 1370
33. M.F. Gagnadoux, R. Habib, M.C. Gubler, J.L. Bacri, M. Broyer Long-term (15-25 years) outcome of childhood hemolytic-uremic syndrome Clin Nephrol 46 1 1996 39 41
34. A. Schlieper, E. Orrbine, G.A. Wells, M. Clulow, P.N. McLaine, P.C. Rowe Neuropsychological sequelae of haemolytic uraemic syndrome Investigators of the HUS Cognitive Study Arch Dis Child 80 3 1999 214 220
35. G. Remuzzi, M. Galbusera, M. Salvadori, G. Rizzoni, S. Paris, P. Ruggenenti Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma Kidney Int 49 1 1996 282 286
36. J. Caprioli, M. Noris, S. Brioschi Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome Blood 108 4 2006 1267 1279
37. E.B. Arenson Jr, C.S. August Preliminary report: treatment of the hemolytic-uremic syndrome with aspirin and dipyridamole J Pediatr 86 6 1975 957 961
38. E.L. Amorosi, S. Karpatkin Antiplatelet treatment of thrombotic thrombocytopenic purpura Ann Intern Med 86 1 1977 102 106
39. E. Bobbio-Pallavicini, L. Gugliotta, R. Centurioni Antiplatelet agents in thrombotic thrombocytopenic purpura (TTP) Results of a randomized multicenter trial by the Italian Cooperative Group for TTP Haematologica 82 4 1997 429 435
40. G.J. del Zoppo Antiplatelet therapy in thrombotic thrombocytopenic purpura Semin Hematol 24 2 1987 130 139
41. W.Y. Au, A.K. Lie, C.C. Lam Tacrolimus (FK 506) induced thrombotic thrombocytopenic purpura after ABO mismatched second liver transplantation: salvage with plasmapheresis and prostacyclin Haematologica 85 6 2000 659 662
42. L. Diekmann [Treatment of the hemolytic-uremic syndrome with streptokinase and heparin (author's translation)] Klin Padiatr 192 5 1980 430 435
43. M. Krause, J. Fehr, J. Gmür, G. Keusch, P. Frick, O. Oelz [Microangiopathic hemolytic anemias. Clinical pattern, therapy and clinical course in 14 patients with thrombotic thrombocytopenic purpura and hemolytic uremic syndrome] Schweiz Med Wochenschr 116 48 1986 1666 1674
44. R. Centurioni, E. Bobbio-Pallavicini, C. Porta Treatment of thrombotic thrombocytopenic purpura with high-dose immunoglobulins Results in 17 patients. Italian Cooperative Group for TTP Haematologica 80 4 1995 325 331
45. P.S. Reddy, D. Deauna-Limayo, J.D. Cook Rituximab in the treatment of relapsed thrombotic thrombocytopenic purpura Ann Hematol 84 4 2005 232 235
46. P. Chamouni, P. Lenain, G. Buchonnet Difficulties in the management of an incomplete form of refractory thrombotic thrombocytopenic purpura, the usefulness of vincristine Transfus Sci 23 2 2000 101 106
47. R. Bruni, G. Giannini, G. Lercari Cascade filtration for TTP: an effective alternative to plasma exchange with cryodepleted plasma Transfus Sci 21 3 1999 193 199
48. K.H. Shumak, G.A. Rock Therapeutic plasma exchange N Engl J Med 310 12 1984 762 771
49. G.A. Rock, K.H. Shumak, N.A. Buskard Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura Canadian Apheresis Study Group N Engl J Med 325 6 1991 393 397
50. P.F. Leblond, G. Rock, C.A. Herbert The use of plasma as a replacement fluid in plasma exchange Canadian Apheresis Group Transfusion (Paris) 38 9 1998 834 838
51. D. Barz, U. Budde, P. Hellstern Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes Thromb Res 107 suppl 1 2002 S23 S27
52. J.M. Saland, S.H. Emre, B.L. Shneider Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation Am J Transplant 6 8 2006 1948 1952
53. A. Büttner-Mainik, J. Parsons, H. Jérôme Production of biologically active recombinant human factor H in Physcomitrella Plant Biotechnol J 9 3 2011 373 383
54. G. Remuzzi, P. Ruggenenti, D. Codazzi Combined kidney and liver transplantation for familial haemolytic uraemic syndrome Lancet 359 9318 2002 1671 1672
55. J.M. Saland, P. Ruggenenti, G. Remuzzi Liver-kidney transplantation to cure atypical hemolytic uremic syndrome J Am Soc Nephrol 20 5 2009 940 949
56. J. Zuber, Q.M. Le, R. Sberro-Soussan, C. Loirat, V. Frémeaux- Bacchi, C. Legendre New insights into postrenal transplant hemolytic uremic syndrome Nat Rev Nephrol 7 1 2011 23 35
57. Solaris (eculizumab) [prescribing information] 2012 Alexion Pharmaceuticals Cheshire, CT
58. P. Hillmen, P. Muus, U. Dührsen Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria Blood 110 12 2007 4123 4128
59. R.A. Brodsky Advances in the diagnosis and therapy of paroxysmal nocturnal hemoglobinuria Blood Rev 22 2 2008 65 74
60. P. Hillmen, M. Elebute, R. Kelly Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria Am J Hematol 85 8 2010 553 559
61. C.J. Mache, B. Acham-Roschitz, V. Fremeaux-Bacchi Complement inhibitor eculizumab in atypical hemolytic uremic syndrome Clin J Am Soc Nephrol 4 8 2009 1312 1316
62. O. Köse, L.B. Zimmerhackl, T. Jungraithmayr, C. Mache, J. Nürnberger New treatment options for atypical hemolytic uremic syndrome with the complement inhibitor eculizumab Semin Thromb Hemost 36 6 2010 669 672
63. S. Tschumi, M. Gugger, B.S. Bucher, M. Riedl, G.D. Simonetti Eculizumab in atypical hemolytic uremic syndrome: long-term clinical course and histological findings Pediatr Nephrol 26 11 2011 2085 2088
64. V. Chatelet, V. Fremeaux-Bacchi, T. Lobbedez, M. Ficheux, L.B. Hurault de Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome Am J Transplant 9 11 2009 2644 2645
65. C.S. Rinder, H.M. Rinder, B.R. Smith Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation J Clin Invest 96 3 1995 1564 1572
66. R. Kelly, L. Arnold, S. Richards Modification of the eculizumab dose to successfully manage intravascular breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria [abstract] ASH Annual Meeting Abstracts 112 11 2008 3441
67. G. Peter, M.B. Weigert, A.R. Bissel, R. Gold, D. Kreutzer, R.H. McLean Meningococcal meningitis in familial deficiency of the fifth component of complement Pediatrics 67 6 1981 882 886
68. S.C. Ross, P. Densen Complement deficiency states and infection: epidemiology, pathogenesis and consequences of neisserial and other infections in an immune deficiency Medicine (Baltimore) 63 5 1984 243 273
69. A. Gianella-Borradori, L. Borradori, P.M. Schneider, E. Gautier, P.J. Spath Combined complete C5 and partial C4 deficiency in humans: clinical consequences and complement-mediated functions in vitro Clin Immunol Immunopathol 55 1 1990 41 55
70. D.M. Granoff Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease Vaccine 27 suppl 2 2009 B117 B125
71. S. Davila, V.J. Wright, C.C. Khor Genome-wide association study identifies variants in the CFH region associated with host susceptibility to meningococcal disease Nat Genet 42 9 2010 772 776
72. C. Parker Eculizumab for paroxysmal nocturnal haemoglobinuria Lancet 373 9665 2009 759 767
73. P. Gardner Clinical practice Prevention of meningococcal disease N Engl J Med 355 14 2006 1466 1473
74. A. Bouts, L. Monnens, J.C. Davin, G. Struijk, L. Spanjaard Insufficient protection by Neisseria meningitidis vaccination alone during eculizumab therapy Pediatr Nephrol 26 10 2011 1919 1920
75. M.D. Stegall, T. Diwan, S. Raghavaiah Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients Am J Transplant 11 11 2011 2405 2413
76. P.K. Smith, S.K. Shernan, J.C. Chen Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: combined results from the PRIMO-CABG I and II trials J Thorac Cardiovasc Surg 142 1 2011 89 98
77. F. Fakhouri, V. Frémeaux-Bacchi, L.H. Noël, H.T. Cook, M.C. Pickering C3 glomerulopathy: a new classification Nat Rev Nephrol 6 8 2010 494 499
78. S. Radhakrishnan, A. Lunn, M. Kirschfink Eculizumab and refractory membranoproliferative glomerulonephritis N Engl J Med 366 12 2012 1165 1166
79. S. Hamour, A.D. Salama, C.D. Pusey Management of ANCA-associated vasculitis: current trends and future prospects Ther Clin Risk Manag 6 2010 253 264
80. A.L. Lapeyraque, M. Malina, V. Frémeaux-Bacchi Eculizumab in severe Shiga-toxin-associated HUS N Engl J Med 364 26 2011 2561 2563
81. E. Colic, H. Dieperink, K. Titlestad, M. Tepel Management of an acute outbreak of diarrhoea-associated haemolytic uraemic syndrome with early plasma exchange in adults from southern Denmark: an observational study Lancet 378 9796 2011 1089 1093
82. K. Kupferschmidt Germany Scientists rush to study genome of lethal E. coli Science 332 6035 2011 1249 1250
83. K. Kupferschmidt Epidemiology Outbreak detectives embrace the genome era Science 333 6051 2011 1818 1819